Gene ID number

7046

Modification site

None

Conjugation

Cy5.5

Swiss Prot

P36897

Subcellular location

Cytoplasm

French translation

anticorps

Modification

Unmodified

Clonality

Polyclonal

Immunogen_range

310-360/501

Additional conjugation

Cy5.5,Cy5.5

Excitation Emission

675nm/694nm

Concentration

1ug per 1ul

Tested applications

FCM, IF(IHC-P)

Crossreactivity

Human, Mouse, Rat

Target Antigen

TGF beta Receptor I

Clone

Polyclonal antibody

Category

Conjugated Primary Antibodies

Host Organism

Rabbit (Oryctolagus cuniculus)

Recommended dilutions

FCM(1:20-100), IF(IHC-P)(1:50-200)

Purification method

This antibody was purified via Protein A.

Long name

TGF Beta R1 Polyclonal Antibody, Cy5.5 Conjugated

Source

KLH conjugated synthetic peptide derived from human TGF-beta R1

Specificity

This is a highly specific antibody against TGF beta Receptor I.

Conjugated

These antibodies are excite for emission at 678nm and detected at a 694 nm wavelengths.

Crossreactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Storage conditions

Keep the antibody in an aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store refrigerated at 2 to 8 degrees Celcius for up to 1 year.

Properties

If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.Cy5 antibodies are excited by the 650-nanometer wave of an argon laser and detected at a 670-nanometer captor.

Synonyms

AAT5; ALK5; ESS1; LDS1; MSSE; SKR4; ALK-5; LDS1A; LDS2A; TGFR-1; ACVRLK4; TGF-beta receptor type-1; Activin A receptor type II-like protein kinase of 53kD; Activin receptor-like kinase 5; Serine/threonine-protein kinase receptor R4; TGF-beta type I receptor; Transforming growth factor-beta receptor type I; TGF-beta receptor type I; TbetaR-I; TGFBR1

Antigen background

Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.